Royal London Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $64.3M | Sell |
213,589
-1,486
| -0.7% | -$448K | 0.12% | 155 |
|
|
2026
Q1 | $71.2M | Sell |
215,075
-37,997
| -15% | -$12.9M | 0.15% | 134 |
|
|
2025
Q4 | $101M | Sell |
253,072
-4,241
| -2% | -$1.88M | 0.21% | 88 |
|
|
2025
Q3 | $117M | Sell |
257,313
-1,758
| -0.7% | -$716K | 0.25% | 73 |
|
|
2025
Q2 | $84.5M | Sell |
259,071
-27,872
| -10% | -$7.71M | 0.19% | 102 |
|
|
2025
Q1 | $77.5M | Buy |
286,943
+5,434
| +2% | +$1.4M | 0.18% | 104 |
|
|
2024
Q4 | $66.2M | Buy |
281,509
+1,759
| +0.6% | +$463K | 0.16% | 109 |
|
|
2024
Q3 | $76.9M | Sell |
279,750
-2,595
| -0.9% | -$676K | 0.19% | 100 |
|
|
2024
Q2 | $68.6M | Sell |
282,345
-44,524
| -14% | -$7.03M | 0.18% | 98 |
|
|
2024
Q1 | $48.9M | Buy |
326,869
+18,045
| +6% | +$3.01M | 0.12% | 146 |
|
|
2023
Q4 | $59.1M | Buy |
308,824
+2,229
| +0.7% | +$380K | 0.17% | 114 |
|
|
2023
Q3 | $54.3M | Buy |
306,595
+142,357
| +87% | +$27.2M | 0.18% | 110 |
|
|
2023
Q2 | $31.2M | Buy |
164,238
+39,467
| +32% | +$7.82M | 0.1% | 163 |
|
|
2023
Q1 | $25M | Buy |
124,771
+82,693
| +197% | +$17.4M | 0.1% | 171 |
|
|
2022
Q4 | $9.99M | Buy |
42,078
+1,436
| +4% | +$306K | 0.04% | 325 |
|
|
2022
Q3 | $8.13M | Sell |
40,642
-1,769
| -4% | -$337K | 0.04% | 337 |
|
|
2022
Q2 | $6.19M | Buy |
42,411
+851
| +2% | +$121K | 0.03% | 400 |
|
|
2022
Q1 | $6.79M | Buy |
41,560
+1,257
| +3% | +$192K | 0.03% | 424 |
|
|
2021
Q4 | $6.84M | Sell |
40,303
-977
| -2% | -$182K | 0.03% | 425 |
|
|
2021
Q3 | $7.8M | Sell |
41,280
-1,112
| -3% | -$209K | 0.03% | 380 |
|
|
2021
Q2 | $7.18M | Hold |
42,392
| – | – | 0.03% | 417 |
|
|
2021
Q1 | $5.99M | Buy |
42,392
+756
| +2% | +$114K | 0.03% | 441 |
|
|
2020
Q4 | $5.42M | Sell |
41,636
-1,047
| -2% | -$140K | 0.03% | 428 |
|
|
2020
Q3 | $6.19M | Buy |
42,683
+1,975
| +5% | +$281K | 0.04% | 345 |
|
|
2020
Q2 | $6.03M | Hold |
40,708
| – | – | 0.04% | 344 |
|
|
2020
Q1 | $4.43M | Hold |
40,708
| – | – | 0.04% | 394 |
|
|
2019
Q4 | $4.67M | Buy |
40,708
+751
| +2% | +$74.9K | 0.03% | 446 |
|
|
2019
Q3 | $3.21M | Buy |
39,957
+2,919
| +8% | +$231K | 0.02% | 515 |
|
|
2019
Q2 | $2.69M | Buy |
37,038
+744
| +2% | +$57.1K | 0.03% | 456 |
|
|
2019
Q1 | $3.39M | Sell |
36,294
-30,509
| -46% | -$2.55M | 0.03% | 516 |
|
|
2018
Q4 | $4.7M | Buy |
66,803
+9,566
| +17% | +$736K | 0.04% | 421 |
|
|
2018
Q3 | $5.01M | Buy |
57,237
+85
| +0.1% | +$8.55K | 0.05% | 339 |
|
|
2018
Q2 | $5.63M | Buy |
+57,152
| New | +$5.67M | 0.06% | 348 |
|
|
2016
Q2 | $3.9M | Buy |
70,380
+52,380
| +291% | +$3.3M | 0.06% | 320 |
|
|
2016
Q1 | $1.13M | Sell |
18,000
-52,047
| -74% | -$3.46M | 0.03% | 490 |
|
|
2015
Q4 | $6.62M | Buy |
70,047
+1,789
| +3% | +$166K | 0.1% | 208 |
|
|
2015
Q3 | $5.49M | Buy |
+68,258
| New | +$7.58M | 0.09% | 242 |
|
|
2014
Q4 | $2.67M | Sell |
27,500
-1,300
| -5% | -$120K | 0.05% | 380 |
|
|
2014
Q3 | $2.26M | Hold |
28,800
| – | – | 0.06% | 350 |
|
|
2014
Q2 | $1.65M | Buy |
28,800
+3,400
| +13% | +$202K | 0.04% | 456 |
|
|
2014
Q1 | $1.46M | Buy |
+25,400
| New | +$1.97M | 0.03% | 491 |
|
Other funds holding ALNY
Royal London Asset Management's ALNY Position: Q2 2026 in Review
Royal London Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.69% in Q2 2026, selling an estimated $448K and leaving 213,589 shares worth $64.3M. The position accounts for 0.12% of the portfolio, ranked #155.
Royal London Asset Management first reported a position in ALNY in Q1 2014 and has held it in 41 quarters since. The position peaked at $117M in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Royal London Asset Management held 213,589 shares of Alnylam Pharmaceuticals worth $64.3M as of Q2 2026.
- Royal London Asset Management sold 1,486 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $448K.
- Alnylam Pharmaceuticals made up 0.12% of Royal London Asset Management's portfolio in Q2 2026, its #155 holding.
- Royal London Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and has held it in 41 quarters since.
- Royal London Asset Management's Alnylam Pharmaceuticals position peaked at $117M in Q3 2025.
- 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.